This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Learn about the efficacy and safety of Somavert, its tumour impact and its effect on co-morbidity management through clinical and real world data

The acromegaly disease activity tool designed to help monitor your patients

Advice and support services to help you and your patients optimise your experience with Somavert about the efficacy and safety of Somavert through clinical and real world data

Learn about funding and reimbursement England, Scotland, Wales and Northern Ireland

Watch and listen to acromegaly experts talk about various topics in the disease area as well as recordings from our National Nurse Meeting and the Acromegaly co-morbidity series

Click here for Somavert® (pegvisomant) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Somavert is used in the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-I concentrations or was not tolerated.

Acromegaly Expert Webinars

Radiotherapy in acromegaly

Dr Sara Meade, Consultant Clinical Oncologist, University Hospitals Birmingham, provides a brief introduction to acromegaly and its treatment with radiotherapy and radiosurgery

Colonic screening acromegaly 

Professor Aled Rees, Consultant in Endocrinology, University Hospital of Wales, Cardiff,explains how active acromegaly can increase the risk of colon cancer, discusses implications of the condition on screening methods and frequency, and shares a colon surveillance algorithm

Treatment impact on diabetes 

Professor Partha Kar, Consultant in Diabetes and Endocrinology, Portsmouth Hospital NHS Trust, discusses the impact of acromegaly and its treatments on glycaemic control and diabetes 

The importance of psychology 

Dr Sue Jackson, Research Psychologist, University of Plymouth, discusses the importance of holistic support that considers the psychological impacts of acromegaly 

The role of the general hospital

Dr Manjusha Rathi, Consultant Endocrinologist, Sherwood Hospitals NHS Foundation Trust discusses the role of the general hospital for a typical acromegaly patient


Card CTA

** This is an optional area where footnotes can live.

The role of the pharmacist

Vicky Ruszala, Specialist Pharmacist in Diabetes and Endocrinology, North Bristol NHS Trust explains the main roles of the pharmacist from medicines optimisation and England-specific BlueTeq funding arrangements to homecare service provision

Card CTA

** This is an optional area where footnotes can live.

Gender considerations

Dr Tara Kearney, Consultant in Endocrinology, Salford Royal Hospital, explains the typical gender differences seen in acromegaly patients, from delays in diagnosis to increased mortality rate


Card CTA

** This is an optional area where footnotes can live.

22 years experience with Somavert

Professor AJ van der Lely, Erasmus MC, Rotterdam, Netherlands, discusses the history of clinical experience with Somavert and the latest data from ACROSTUDY, a global post-marketing surveillance study

Card CTA

** This is an optional area where footnotes can live.

Explore more

Contact us

To find out more about ACRODAT, supporting your patients or to order starter kits 

Contact us

** This is an optional area where footnotes can live.

Acromegaly co-morbidities webinars

Watch and listen to our Rare Disease Insight series where expert speakers take a deep dive into the co-morbidities associated with acromegaly

Watch the webinars here

** This is an optional area where footnotes can live.

National Nurse Meeting Recordings

Watch recordings from the 2020 national nurse meeting with discussions on enhancing nurse competency, acromegaly co-morbidities and auditing pituitary disorders

Watch the recordings here

** This is an optional area where footnotes can live.

PP-SOM-GBR-0957. June 2021

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020